Heather Turner
Chief Executive Officer chez Carmot Therapeutics, Inc.
Profil
Heather D.
Turner is currently the President, Chief Executive Officer & Director at Carmot Therapeutics, Inc. She is also a Member at The State Bar of California.
Previously, she held positions as the Senior Vice President & General Counsel at Sangamo Therapeutics, Inc. from 2018 to 2019, Associate General Counsel at Conor Medsystems LLC from 2005 to 2007, Secretary, Senior Vice President & General Counsel at Orexigen Therapeutics, Inc. from 2007 to 2015, and Associate at Cooley LLP from 1999 to 2005.
Additionally, she served as the Secretary, Executive VP & General Counsel at Atara Biotherapeutics, Inc. from 2015 to 2018, and as the Secretary & Chief General Counsel at Lyell Immunopharma, Inc. from 2019 to 2023.
Ms. Turner obtained her undergraduate degree from the University of California, Santa Barbara and her graduate degree from UCLA School of Law.
Postes actifs de Heather Turner
| Sociétés | Poste | Début |
|---|---|---|
The State Bar of California
 The State Bar of California Miscellaneous Commercial ServicesCommercial Services The State Bar of California operates as an official attorney licensing agency. The non-profit company is based in San Francisco, CA. Elizabeth Rindskopf Parker has been the CEO of the company since 2015. | Corporate Officer/Principal | - |
Carmot Therapeutics, Inc.
 Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | Chief Executive Officer | 01/01/2023 |
Anciens postes connus de Heather Turner
| Sociétés | Poste | Fin |
|---|---|---|
| LYELL IMMUNOPHARMA, INC. | General Counsel | 05/07/2023 |
| SANGAMO THERAPEUTICS, INC. | General Counsel | 15/03/2019 |
| ATARA BIOTHERAPEUTICS, INC. | General Counsel | 01/02/2018 |
| OREXIGEN THERAPEUTICS, INC. | General Counsel | 25/06/2015 |
Conor Medsystems LLC
 Conor Medsystems LLC Medical SpecialtiesHealth Technology Conor Medsystems LLC develops vascular drug delivery technologies. Its products include controlled vascular drug delivery technologies and novel stent that are used in the treatment of coronary artery disease and delivery of a broad spectrum of therapeutic agents. The company was founded by John F. Shanley in 1999 and is headquartered in Menlo Park, CA. | Corporate Officer/Principal | 01/06/2007 |
Formation de Heather Turner
| University of California, Santa Barbara | Undergraduate Degree |
| UCLA School of Law | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| SANGAMO THERAPEUTICS, INC. | Health Technology |
| LYELL IMMUNOPHARMA, INC. | Health Technology |
| ATARA BIOTHERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
Conor Medsystems LLC
Conor Medsystems LLC Medical SpecialtiesHealth Technology Conor Medsystems LLC develops vascular drug delivery technologies. Its products include controlled vascular drug delivery technologies and novel stent that are used in the treatment of coronary artery disease and delivery of a broad spectrum of therapeutic agents. The company was founded by John F. Shanley in 1999 and is headquartered in Menlo Park, CA. | Health Technology |
Orexigen Therapeutics, Inc.
 Orexigen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Orexigen Therapeutics, Inc. is a biopharmaceutical company, which focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its primary activities include recruiting personnel, conducting research and development, including clinical trials, raising capital, and preparing for the marketing and commercialization of its product, contrave. The company was founded by Eckard Weber in September 2002 and is headquartered in La Jolla, CA. | Health Technology |
Cooley LLP
 Cooley LLP Miscellaneous Commercial ServicesCommercial Services Cooley LLP engages in the provision of legal services. It offers strategic litigation and business transaction services and is a representative of private and public companies, financial institutions, venture capital firms and nonprofit organizations. Its practices include commercial litigation; patent counseling and prosecution; employment and labor; asset recovery; and estate planning and personal representation. The company was founded in 1920 and is headquartered in New York, NY. | Commercial Services |
The State Bar of California
The State Bar of California Miscellaneous Commercial ServicesCommercial Services The State Bar of California operates as an official attorney licensing agency. The non-profit company is based in San Francisco, CA. Elizabeth Rindskopf Parker has been the CEO of the company since 2015. | Commercial Services |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | Health Technology |
